Treatment Information

Back

Breast Cancer treatment details. Biologic therapy.

University Hospital Gasthuisberg, Leuven, Belgium.

Survival: monthsCountry:Belgium
Toxiciy Grade:4City/State/Province:Leuven
Treatments:Biologic therapyHospital:University Hospital Gasthuisberg
Drugs:Journal:Link
Date:Oct 2008

Description:

Patients: This phase 3 study involved 371 women with metastatic breast cancer. All the women in this trial were post-menopausal. The median age was 63, ranging from 37 to 87 years of age.

Treatment: These women were treated with either exemestane or tamoxifen, both of which are biological therapies. Tamoxifen works on the estrogen-receptor, and exemestane is and aromatase inhibitor.

Toxicity: Grade 3 and 4 toxicities were not very common. Grade 3 and 4 toxicities included hypertension, bone pain, neutropenia, and dyspnea. The most common grade 3 or 4 toxicity (other than changes in blood chemistry) was bone pain, occurring in 5.8% of women treated with tamoxifen.

Results: The median overall survival was 43.3 months for women treated with tamoxifen, and 37.2 months for those treated with exemestane.

Support: This research was supported in part by funds from Pfizer, Inc, which markets exemestane as Aromasin®.

Correspondence: Dr. Robert J. Paridaens





Back